Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).

Journal of hepatology

Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M.
PMID: 32654856
J Hepatol. 2020 Sep;73(3):740-741. doi: 10.1016/j.jhep.2020.06.018. Epub 2020 Jul 09.

No abstract available.

Cite
Ampuero J, Aller R, Gallego-Durán R, et al. Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25). J Hepatol. 2020;73(3):740-741doi: 10.1016/j.jhep.2020.06.018.
Ampuero, J., Aller, R., Gallego-Durán, R., Crespo, J., Calleja, J. L., García-Monzón, C., Gómez-Camarero, J., Caballería, J., Lo Iacono, O., Ibañez, L., García-Samaniego, J., Albillos, A., Francés, R., Fernández-Rodríguez, C., Diago, M., Soriano, G., Andrade, R. J., Latorre, R., Jorquera, F., Morillas, R. M., Escudero, D., Estévez, P., Hernandez-Guerra, M., Augustín, S., Bañales, J., Aspichueta, P., Benlloch, S., Rosales, J. M., Salmerón, J., Turnes, J., Romero-Gómez, M. (2020). Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25). Journal of hepatology, 73(3), 740-741. https://doi.org/10.1016/j.jhep.2020.06.018
Ampuero, Javier, et al. "Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25)." Journal of hepatology vol. 73,3 (2020): 740-741. doi: https://doi.org/10.1016/j.jhep.2020.06.018
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M. Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25). J Hepatol. 2020 Sep;73(3):740-741. doi: 10.1016/j.jhep.2020.06.018. Epub 2020 Jul 09. PMID: 32654856.
Copy Download .nbib Format: NLM
Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease.

EBioMedicine

Metwally M, Bayoumi A, Khan A, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Bugianesi E, Miele L, Anna A, Latchoumanin O, Han S, Alenizi S, Sharkawy RE, Elattar A, Gallego-Durán R, Fischer J, Berg T, Liddle C, Romero-Gomez M, George J, Eslam M.
PMID: 34388518
EBioMedicine. 2021 Aug;70:103521. doi: 10.1016/j.ebiom.2021.103521. Epub 2021 Aug 11.

BACKGROUND: Liver fibrosis risk is a heritable trait, the outcome of which is the net deposition of extracellular matrix by hepatic stellate cell-derived myofibroblasts. Whereas nucleotide sequence variations have been extensively studied in liver fibrosis, the role of copy...

Cite
Metwally M, Bayoumi A, Khan A, et al. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine. 2021;70:103521doi: 10.1016/j.ebiom.2021.103521.
Metwally, M., Bayoumi, A., Khan, A., Adams, L. A., Aller, R., García-Monzón, C., Arias-Loste, M. T., Bugianesi, E., Miele, L., Anna, A., Latchoumanin, O., Han, S., Alenizi, S., Sharkawy, R. E., Elattar, A., Gallego-Durán, R., Fischer, J., Berg, T., Liddle, C., Romero-Gomez, M., George, J., & Eslam, M. (2021). Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 70103521. https://doi.org/10.1016/j.ebiom.2021.103521
Metwally, Mayada, et al. "Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease." EBioMedicine vol. 70 (2021): 103521. doi: https://doi.org/10.1016/j.ebiom.2021.103521
Metwally M, Bayoumi A, Khan A, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Bugianesi E, Miele L, Anna A, Latchoumanin O, Han S, Alenizi S, Sharkawy RE, Elattar A, Gallego-Durán R, Fischer J, Berg T, Liddle C, Romero-Gomez M, George J, Eslam M. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine. 2021 Aug;70:103521. doi: 10.1016/j.ebiom.2021.103521. Epub 2021 Aug 11. PMID: 34388518; PMCID: PMC8365315.
Copy Download .nbib Format: NLM
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349].

Gastroenterologia y hepatologia

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, López Miranda J, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego-Durán R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.
PMID: 29929828
Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476. doi: 10.1016/j.gastrohep.2018.05.011.

No abstract available.

Cite
Aller R, Fernández-Rodríguez C, Lo Iacono O, et al. Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]. Gastroenterol Hepatol. 2018;41(7):475-476doi: 10.1016/j.gastrohep.2018.05.011.
Aller, R., Fernández-Rodríguez, C., Lo Iacono, O., Bañares, R., Abad, J., Carrión, J. A., García-Monzón, C., Caballería, J., Berenguer, M., Rodríguez-Perálvarez, M., López Miranda, J., Vilar-Gómez, E., Crespo, J., García-Cortés, M., Reig, M., Navarro, J. M., Gallego-Durán, R., Genescà, J., Arias-Loste, M. T., Pareja, M. J., Albillos, A., Muntané, J., Jorquera, F., Solà, E., Hernández-Guerra, M., Rojo, M. �. �., Salmerón, J., Caballería, L., Diago, M., Molina, E., Bataller, R., & Romero-Gómez, M. (2018). Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]. Gastroenterologia y hepatologia, 41(7), 475-476. https://doi.org/10.1016/j.gastrohep.2018.05.011
Aller, Rocío, et al. "Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]." Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]. Gastroenterologia y hepatologia vol. 41,7 (2018): 475-476. doi: https://doi.org/10.1016/j.gastrohep.2018.05.011
Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, López Miranda J, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego-Durán R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]. Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476. doi: 10.1016/j.gastrohep.2018.05.011. Spanish. PMID: 29929828.
Copy Download .nbib Format: NLM
Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.

Clinical and translational medicine

Rey E, Ampuero J, Molina-Jiménez F, Marañón P, García-García Y, Múñoz-Hernández R, Romero-Gómez M, García-Monzón C, Majano P, González-Rodríguez Á.
PMID: 33463051
Clin Transl Med. 2021 Jan;11(1):e275. doi: 10.1002/ctm2.275.

No abstract available.

Cite
Rey E, Ampuero J, Molina-Jiménez F, et al. Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clin Transl Med. 2021;11(1):e275doi: 10.1002/ctm2.275.
Rey, E., Ampuero, J., Molina-Jiménez, F., Marañón, P., García-García, Y., Múñoz-Hernández, R., Romero-Gómez, M., García-Monzón, C., Majano, P., & González-Rodríguez, �. �. (2021). Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clinical and translational medicine, 11(1), e275. https://doi.org/10.1002/ctm2.275
Rey, Esther, et al. "Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation." Clinical and translational medicine vol. 11,1 (2021): e275. doi: https://doi.org/10.1002/ctm2.275
Rey E, Ampuero J, Molina-Jiménez F, Marañón P, García-García Y, Múñoz-Hernández R, Romero-Gómez M, García-Monzón C, Majano P, González-Rodríguez Á. Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. Clin Transl Med. 2021 Jan;11(1):e275. doi: 10.1002/ctm2.275. PMID: 33463051; PMCID: PMC7810262.
Copy Download .nbib Format: NLM
Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Bayoumi A, Elsayed A, Han S, Petta S, Adams LA, Aller R, Khan A, García-Monzón C, Arias-Loste MT, Miele L, Latchoumanin O, Alenizi S, Gallego-Durán R, Fischer J, Berg T, Craxì A, Metwally M, Qiao L, Liddle C, Yki-Järvinen H, Bugianesi E, Romero-Gomez M, George J, Eslam M.
PMID: 34141520
Adv Sci (Weinh). 2021 May 01;8(11):2004168. doi: 10.1002/advs.202004168. eCollection 2021 Jun.

Fibroblast growth factor 21 (FGF21) is a liver-derived hormone with pleiotropic beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in metabolic diseases. Interventions that restore metabolic homeostasis reduce FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral...

Cite
Bayoumi A, Elsayed A, Han S, et al. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Adv Sci (Weinh). 2021;8(11):2004168doi: 10.1002/advs.202004168.
Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L. A., Aller, R., Khan, A., García-Monzón, C., Arias-Loste, M. T., Miele, L., Latchoumanin, O., Alenizi, S., Gallego-Durán, R., Fischer, J., Berg, T., Craxì, A., Metwally, M., Qiao, L., Liddle, C., Yki-Järvinen, H., Bugianesi, E., Romero-Gomez, M., George, J., & Eslam, M. (2021). Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(11), 2004168. https://doi.org/10.1002/advs.202004168
Bayoumi, Ali, et al. "Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus." Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 8,11 (2021): 2004168. doi: https://doi.org/10.1002/advs.202004168
Bayoumi A, Elsayed A, Han S, Petta S, Adams LA, Aller R, Khan A, García-Monzón C, Arias-Loste MT, Miele L, Latchoumanin O, Alenizi S, Gallego-Durán R, Fischer J, Berg T, Craxì A, Metwally M, Qiao L, Liddle C, Yki-Järvinen H, Bugianesi E, Romero-Gomez M, George J, Eslam M. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Adv Sci (Weinh). 2021 May 01;8(11):2004168. doi: 10.1002/advs.202004168. eCollection 2021 Jun. PMID: 34141520; PMCID: PMC8188187.
Copy Download .nbib Format: NLM
Research update for articles published in EJCI in 2014.

European journal of clinical investigation

Agra RM, Al-Daghri NM, Badimon L, Bodi V, Carbone F, Chen M, Cubedo J, Dullaart RP, Eiras S, García-Monzón C, Gary T, Gnoni A, González-Rodríguez Á, Gremmel T, Hafner F, Hakala T, Huang B, Ickmans K, Irace C, Kholová I, Kimer N, Kytö V, März W, Miazgowski T, Møller S, Montecucco F, Niccoli G, Nijs J, Ozben S, Ozben T, Papassotiriou I, Papastamataki M, Reina-Couto M, Rios-Navarro C, Ritsch A, Sabico S, Seetho IW, Severino A, Sipilä J, Sousa T, Taszarek A, Taurino F, Tietge UJ, Tripolino C, Verloop W, Voskuil M, Wilding JP.
PMID: 27571922
Eur J Clin Invest. 2016 Oct;46(10):880-94. doi: 10.1111/eci.12671.

No abstract available.

Cite
Agra RM, Al-Daghri NM, Badimon L, et al. Research update for articles published in EJCI in 2014. Eur J Clin Invest. 2016;46(10):880-94doi: 10.1111/eci.12671.
Agra, R. M., Al-Daghri, N. M., Badimon, L., Bodi, V., Carbone, F., Chen, M., Cubedo, J., Dullaart, R. P., Eiras, S., García-Monzón, C., Gary, T., Gnoni, A., González-Rodríguez, �. �., Gremmel, T., Hafner, F., Hakala, T., Huang, B., Ickmans, K., Irace, C., Kholová, I., Kimer, N., Kytö, V., März, W., Miazgowski, T., Møller, S., Montecucco, F., Niccoli, G., Nijs, J., Ozben, S., Ozben, T., Papassotiriou, I., Papastamataki, M., Reina-Couto, M., Rios-Navarro, C., Ritsch, A., Sabico, S., Seetho, I. W., Severino, A., Sipilä, J., Sousa, T., Taszarek, A., Taurino, F., Tietge, U. J., Tripolino, C., Verloop, W., Voskuil, M., & Wilding, J. P. (2016). Research update for articles published in EJCI in 2014. European journal of clinical investigation, 46(10), 880-94. https://doi.org/10.1111/eci.12671
Agra, Rosa María, et al. "Research update for articles published in EJCI in 2014." European journal of clinical investigation vol. 46,10 (2016): 880-94. doi: https://doi.org/10.1111/eci.12671
Agra RM, Al-Daghri NM, Badimon L, Bodi V, Carbone F, Chen M, Cubedo J, Dullaart RP, Eiras S, García-Monzón C, Gary T, Gnoni A, González-Rodríguez Á, Gremmel T, Hafner F, Hakala T, Huang B, Ickmans K, Irace C, Kholová I, Kimer N, Kytö V, März W, Miazgowski T, Møller S, Montecucco F, Niccoli G, Nijs J, Ozben S, Ozben T, Papassotiriou I, Papastamataki M, Reina-Couto M, Rios-Navarro C, Ritsch A, Sabico S, Seetho IW, Severino A, Sipilä J, Sousa T, Taszarek A, Taurino F, Tietge UJ, Tripolino C, Verloop W, Voskuil M, Wilding JP. Research update for articles published in EJCI in 2014. Eur J Clin Invest. 2016 Oct;46(10):880-94. doi: 10.1111/eci.12671. PMID: 27571922.
Copy Download .nbib Format: NLM
Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice.

Disease models & mechanisms

López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó.
PMID: 34850865
Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049173. Epub 2021 Dec 24.

The prevalence of non-alcoholic fatty liver disease (NAFLD) is constantly increasing, and altered expression of microRNAs (miRNAs) fosters the development and progression of many pathologies, including NAFLD. Therefore, we explored the role of new miRNAs involved in the molecular...

Cite
López-Pastor AR, Infante-Menéndez J, González-Illanes T, et al. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech. 2021;14(12)doi: 10.1242/dmm.049173.
López-Pastor, A. R., Infante-Menéndez, J., González-Illanes, T., González-López, P., González-Rodríguez, �. �., García-Monzón, C., Vega de Céniga, M., Esparza, L., Gómez-Hernández, A., & Escribano, �. �. (2021). Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Disease models & mechanisms, 14(12), . https://doi.org/10.1242/dmm.049173
López-Pastor, Andrea R, et al. "Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice." Disease models & mechanisms vol. 14,12 (2021). doi: https://doi.org/10.1242/dmm.049173
López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049173. Epub 2021 Dec 24. PMID: 34850865.
Copy Download .nbib Format: NLM
Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice.

Disease models & mechanisms

López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó.
PMID: 34850865
Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049173. Epub 2021 Dec 24.

The prevalence of non-alcoholic fatty liver disease (NAFLD) is constantly increasing, and altered expression of microRNAs (miRNAs) fosters the development and progression of many pathologies, including NAFLD. Therefore, we explored the role of new miRNAs involved in the molecular...

Cite
López-Pastor AR, Infante-Menéndez J, González-Illanes T, et al. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech. 2021;14(12)doi: 10.1242/dmm.049173.
López-Pastor, A. R., Infante-Menéndez, J., González-Illanes, T., González-López, P., González-Rodríguez, �. �., García-Monzón, C., Vega de Céniga, M., Esparza, L., Gómez-Hernández, A., & Escribano, �. �. (2021). Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Disease models & mechanisms, 14(12), . https://doi.org/10.1242/dmm.049173
López-Pastor, Andrea R, et al. "Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice." Disease models & mechanisms vol. 14,12 (2021). doi: https://doi.org/10.1242/dmm.049173
López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049173. Epub 2021 Dec 24. PMID: 34850865; PMCID: PMC8713993.
Copy Download .nbib Format: NLM
Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea.

Frontiers in medicine

Rey E, Del Pozo-Maroto E, Marañón P, Beeler B, García-García Y, Landete P, Isaza SC, Farré R, García-Monzón C, Almendros I, González-Rodríguez Á.
PMID: 32850919
Front Med (Lausanne). 2020 Aug 11;7:450. doi: 10.3389/fmed.2020.00450. eCollection 2020.

Nocturnal intermittent hypoxia (IH) featuring obstructive sleep apnea (OSA) dysregulates hepatic lipid metabolism and might contribute to the development of non-alcoholic fatty liver disease (NAFLD) observed in OSA patients. However, further research is required to better understanding the molecular...

Cite
Rey E, Del Pozo-Maroto E, Marañón P, et al. Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea. Front Med (Lausanne). 2020;7:450doi: 10.3389/fmed.2020.00450.
Rey, E., Del Pozo-Maroto, E., Marañón, P., Beeler, B., García-García, Y., Landete, P., Isaza, S. C., Farré, R., García-Monzón, C., Almendros, I., & González-Rodríguez, �. �. (2020). Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea. Frontiers in medicine, 7450. https://doi.org/10.3389/fmed.2020.00450
Rey, Esther, et al. "Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea." Frontiers in medicine vol. 7 (2020): 450. doi: https://doi.org/10.3389/fmed.2020.00450
Rey E, Del Pozo-Maroto E, Marañón P, Beeler B, García-García Y, Landete P, Isaza SC, Farré R, García-Monzón C, Almendros I, González-Rodríguez Á. Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea. Front Med (Lausanne). 2020 Aug 11;7:450. doi: 10.3389/fmed.2020.00450. eCollection 2020. PMID: 32850919; PMCID: PMC7431763.
Copy Download .nbib Format: NLM
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Gastroenterologia y hepatologia

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.
PMID: 29631866
Gastroenterol Hepatol. 2018 May;41(5):328-349. doi: 10.1016/j.gastrohep.2017.12.003. Epub 2018 Apr 07.

Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver diseases in Spain and the incidence is raising due to the outbreak of type 2 diabetes and obesity. This CPG suggests recommendation about diagnosis, mainly non-invasive biomarkers, and...

Cite
Aller R, Fernández-Rodríguez C, Lo Iacono O, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol. 2018;41(5):328-349doi: 10.1016/j.gastrohep.2017.12.003.
Aller, R., Fernández-Rodríguez, C., Lo Iacono, O., Bañares, R., Abad, J., Carrión, J. A., García-Monzón, C., Caballería, J., Berenguer, M., Rodríguez-Perálvarez, M., Miranda, J. L., Vilar-Gómez, E., Crespo, J., García-Cortés, M., Reig, M., Navarro, J. M., Gallego, R., Genescà, J., Arias-Loste, M. T., Pareja, M. J., Albillos, A., Muntané, J., Jorquera, F., Solà, E., Hernández-Guerra, M., Rojo, M. �. �., Salmerón, J., Caballería, L., Diago, M., Molina, E., Bataller, R., & Romero-Gómez, M. (2018). Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterologia y hepatologia, 41(5), 328-349. https://doi.org/10.1016/j.gastrohep.2017.12.003
Aller, Rocío, et al. "Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica." Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterologia y hepatologia vol. 41,5 (2018): 328-349. doi: https://doi.org/10.1016/j.gastrohep.2017.12.003
Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol. 2018 May;41(5):328-349. doi: 10.1016/j.gastrohep.2017.12.003. Epub 2018 Apr 07. Spanish. PMID: 29631866.
Copy Download .nbib Format: NLM
Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E deficient mice.

Disease models & mechanisms

López-Pastor AR, Infante-Menéndez J, Illanes TG, González-López P, González-Rodríguez Á, García-Monzón C, de Céniga MV, Esparza L, Gómez-Hernández A, Escribano O.
PMID: 34850865
Dis Model Mech. 2021 Dec 01; doi: 10.1242/dmm.049173. Epub 2021 Dec 01.

Non-alcoholic fatty liver disease (NAFLD) prevalence is constantly increasing and microRNAs (miRNAs) altered expression fosters the development and progression of many pathologies, including NAFLD. Therefore, we explored the role of new miRNAs involved in the molecular mechanisms that trigger...

Cite
López-Pastor AR, Infante-Menéndez J, Illanes TG, et al. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E deficient mice. Dis Model Mech. 2021;doi: 10.1242/dmm.049173.
López-Pastor, A. R., Infante-Menéndez, J., Illanes, T. G., González-López, P., González-Rodríguez, �. �., García-Monzón, C., de Céniga, M. V., Esparza, L., Gómez-Hernández, A., & Escribano, O. (2021). Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E deficient mice. Disease models & mechanisms, . https://doi.org/10.1242/dmm.049173
López-Pastor, Andrea R, et al. "Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E deficient mice." Disease models & mechanisms vol. (2021). doi: https://doi.org/10.1242/dmm.049173
López-Pastor AR, Infante-Menéndez J, Illanes TG, González-López P, González-Rodríguez Á, García-Monzón C, de Céniga MV, Esparza L, Gómez-Hernández A, Escribano O. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E deficient mice. Dis Model Mech. 2021 Dec 01; doi: 10.1242/dmm.049173. Epub 2021 Dec 01. PMID: 34850865.
Copy Download .nbib Format: NLM
Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice.

Disease models & mechanisms

López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó.
PMID: 34850865
Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049173. Epub 2021 Dec 24.

The prevalence of non-alcoholic fatty liver disease (NAFLD) is constantly increasing, and altered expression of microRNAs (miRNAs) fosters the development and progression of many pathologies, including NAFLD. Therefore, we explored the role of new miRNAs involved in the molecular...

Cite
López-Pastor AR, Infante-Menéndez J, González-Illanes T, et al. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech. 2021;14(12)doi: 10.1242/dmm.049173.
López-Pastor, A. R., Infante-Menéndez, J., González-Illanes, T., González-López, P., González-Rodríguez, �. �., García-Monzón, C., Vega de Céniga, M., Esparza, L., Gómez-Hernández, A., & Escribano, �. �. (2021). Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Disease models & mechanisms, 14(12), . https://doi.org/10.1242/dmm.049173
López-Pastor, Andrea R, et al. "Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice." Disease models & mechanisms vol. 14,12 (2021). doi: https://doi.org/10.1242/dmm.049173
López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049173. Epub 2021 Dec 24. PMID: 34850865; PMCID: PMC8713993.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries